GANX | Gain Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.5855 - 1.7800
52 Week Range	0.8900 - 5.33
Beta	0.61
Implied Volatility	724.74%
IV Rank	56.88%
Day's Volume	204,040
Average Volume	387,334
Shares Outstanding	26,525,100
Market Cap	45,623,172
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-03-19

Valuation
Profitability
Growth
Health
P/E Ratio	-1.61
Forward P/E Ratio	N/A
EPS	-1.07
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	29
Country	USA
Website	GANX

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

GANX's peers: APLT, APTO, CGTX, BIVI, INAB, NAMS, CUE, TFFP, LIFE, LTRN, ELYM, INBX, MACK, CELC, ELVN, MOLN, MNOV, ANEB, CSBR, CYT, IMNM, PMN, COYA

*Chart delayed

Analyzing fundamentals for GANX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see GANX Fundamentals page.

Watching at GANX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GANX Technicals page.